THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Both legislators, firms split on stem-cell incentives

Debate on support for research poses a test for Finneran

By Ross Kerber
Globe Staff / November 12, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Beacon Hill's new enthusiasm for embryonic stem-cell research would seem to be good news for the biotechnology industry. (Full article: 725 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass